Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) shares traded down 4.3% during trading on Wednesday . The stock traded as low as $8.17 and last traded at $8.21, with a volume of 73,449 shares changing hands. The stock had previously closed at $8.58.

Several research analysts recently commented on the stock. Zacks Investment Research lowered shares of Vitae Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 4th. JMP Securities downgraded shares of Vitae Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 4th. Wedbush reaffirmed an “outperform” rating and issued a $23.00 price objective on shares of Vitae Pharmaceuticals in a research report on Wednesday, May 25th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Vitae Pharmaceuticals in a research report on Friday, June 10th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $16.65.

The company’s market capitalization is $230.15 million. The firm has a 50 day moving average price of $9.95 and a 200-day moving average price of $8.57.

Vitae Pharmaceuticals (NASDAQ:VTAE) last released its earnings results on Wednesday, August 3rd. The company reported ($0.36) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.05. The business’s revenue was down 98.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.45) EPS. On average, analysts expect that Vitae Pharmaceuticals Inc. will post ($1.64) EPS for the current fiscal year.

An institutional investor recently bought a new position in Vitae Pharmaceuticals stock. Dimensional Fund Advisors LP bought a new stake in shares of Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 73,607 shares of the company’s stock, valued at approximately $1,332,000. Dimensional Fund Advisors LP owned about 0.34% of Vitae Pharmaceuticals as of its most recent SEC filing.

Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.